M2 PHARMA-February 22, 2017-Faron Pharmaceuticals enrols first patient in phase II clinical trial
United States-based Samumed has completed a Phase II clinical trial
for its potential treatment of androgenetic alopecia, it was reported yesterday.
The company currently has two products in clinical trials; CBF-BS2, which has just completed Phase II clinical trials
for rheumatoid arthritis; and CB-2431 for osteo-arthritis which has also successfully completed a Phase II clinical trial
M2 PHARMA-January 19, 2017-Evgen Pharma doses first patient in Phase II clinical trial
M2 EQUITYBITES-October 14, 2015-Clearside Biomedical completes enrolment of patients in Phase II clinical trial
In addition, last January NTI completed enrollment in a double-blind, placebo-controlled Phase II clinical trial
of Memantine for AIDS-related dementia funded by the National Institute of Health (NIH) and conducted by the AIDS Clinical Trials Group (ACTG), a clinical consortium funded by the National Institute of Allergy and Infectious Diseases (NIAID).
M2 PHARMA-January 5, 2017-NewVac meets all primary endpoints in Phase II Clinical Trial
GTx, a US-based biopharmaceutical company, has enrolled its first patient in its Phase II clinical trial
of enobosarm (GTx-024), it was reported yesterday.
Immuno-oncology company ImaginAb Inc revealed on Tuesday the launch of its Phase II clinical trial
of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at the Dana-Farber Cancer Institute.
M2 PHARMA-July 24, 2019-ImaginAb begins Phase II clinical trial
of 89Zr-Df-IAB22M2C at Dana-Farber Cancer Institute
Cellular Biomedicine announced that its off-the-shelf allogeneic adipose-derived mesenchymal progenitor cell, or haMPC, AlloJoin therapy for Knee Osteoarthritis, or KOA, has been approved as the first stem cell KOA drug application in China for a Phase II clinical trial
. China NMPA clarified Cell Therapy Regulations in December 2017 whereby all cell therapies are being treated as drug NDA/IND.
NORDIC BUSINESS REPORT-June 22, 2018-Orphazyme enrols first patient in phase II clinical trial
for Gaucher disease